149 related articles for article (PubMed ID: 34671625)
21. Biologics for Non-Cancer Dermatological Diseases: Analysis on China's Clinical Trial Registration Trend From 2016 to 2020.
Zhu B; Liu Y; Li J; Ni Q; Yin Z; Zhu J; Chen K; Yang X
Front Pharmacol; 2022; 13():817065. PubMed ID: 35529441
[No Abstract] [Full Text] [Related]
22. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
[TBL] [Abstract][Full Text] [Related]
23. Pediatric drug development in China: Reforms and challenges.
Wu W; Tang Z; Chen J; Gao Y
Pharmacol Res; 2019 Oct; 148():104412. PubMed ID: 31491470
[TBL] [Abstract][Full Text] [Related]
24. Development of clinical trials for non-small cell lung cancer drugs in China from 2005 to 2023.
Jia W; Yu H; Song L; Wang J; Niu S; Zang G; Liang M; Liu J; Na R
Front Med (Lausanne); 2023; 10():1239351. PubMed ID: 38034540
[TBL] [Abstract][Full Text] [Related]
25. Clinical trials of orphan drugs in China over the decade 2012-2022: Opportunities and challenges.
Wu X; Xu W; Yu M; Zhang F; Wang H
Pharmacol Res; 2022 Aug; 182():106349. PubMed ID: 35835367
[TBL] [Abstract][Full Text] [Related]
26. The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009-2021.
Li C; Hao J; Zheng Y; Wang C; Yang J; Wang W; Zhang K; Shao C; Hui W; Wang J; Li W; Tang YD
Diabetol Metab Syndr; 2023 Apr; 15(1):66. PubMed ID: 37005689
[TBL] [Abstract][Full Text] [Related]
27. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
28. Research and development of mAb drugs in China: a look from policy perspectives.
Jiang R; Sun Y; Ung C; Dong X; Kong X; Hu Y; Shao R
Hum Vaccin Immunother; 2019; 15(11):2695-2705. PubMed ID: 31116629
[No Abstract] [Full Text] [Related]
29. Challenges and opportunities for China entering global research and development for emerging infectious diseases: a case study from Ebola experience.
Li C; Chen JY; Huang YM
Infect Dis Poverty; 2020 Mar; 9(1):27. PubMed ID: 32164743
[TBL] [Abstract][Full Text] [Related]
30. Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020.
Chen K; Jiang K; Tang L; Chen X; Hu J; Sun F
Front Oncol; 2021; 11():647110. PubMed ID: 34084744
[TBL] [Abstract][Full Text] [Related]
31. [Progress on clinical trials of common gastrointestinal cancer drugs in China from 2012 to 2021].
Huang HY; Wu DW; Zhu Q; Yu Y; Wang HX; Wang J; Ga M; Meng XY; Du JT; Miao SM; Zhao ZX; Wang X; Shang P; Guo MJ; Liu LH; Tang Y; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):276-281. PubMed ID: 35316878
[No Abstract] [Full Text] [Related]
32. [Current situation of pediatric emergency in tertiary and teaching hospitals in 15 provinces, municipalities and autonomous regions in China Mainland].
;
Zhonghua Er Ke Za Zhi; 2014 Dec; 52(12):913-7. PubMed ID: 25619348
[TBL] [Abstract][Full Text] [Related]
33. Analysis of Pediatric Oncology Nursing Research in Mainland China, 2008-2018.
Luo YH; Yin SH; Xu J; Challinor J
Cancer Nurs; 2022 Jan-Feb 01; 45(1):E206-E228. PubMed ID: 33214516
[TBL] [Abstract][Full Text] [Related]
34. [Thoughts of the combination of medicine and engineering and collaborative innovation on surgery in China].
Lyu ZJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jun; 23(6):562-565. PubMed ID: 32521975
[TBL] [Abstract][Full Text] [Related]
35. Current clinical trials on breast cancer in China: A systematic literature review.
Fan Y; Xu B
Cancer; 2020 Aug; 126 Suppl 16():3811-3818. PubMed ID: 32710659
[TBL] [Abstract][Full Text] [Related]
36. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
37. Report on the development and application of PET/CT in mainland China.
Chen Y; Chen R; Zhou X; Liu J; Huang G
Oncotarget; 2017 Sep; 8(38):64417-64426. PubMed ID: 28969081
[TBL] [Abstract][Full Text] [Related]
38. The challenge of healthcare big data to China's commercial health insurance industry: evaluation and recommendations.
Wu J; Qiao J; Nicholas S; Liu Y; Maitland E
BMC Health Serv Res; 2022 Sep; 22(1):1189. PubMed ID: 36138390
[TBL] [Abstract][Full Text] [Related]
39. IPDN-China promotes the development of pediatric dialysis in China.
Zhai Y; Liu X; Yang Q; Dang X; Sun S; Shao X; Liu X; Wu Y; Bai H; Mao J; Dong Y; Ma Q; Kang G; Huang W; Zhu H; Fu R; Zhang A; Xu R; Sun Q; Jiang X; Lai L; Huang J; Luan J; Xia Z; Cui J; Zhao M; Wu X; Zhang Q; Li Y; Liu C; Wang M; Wang F; Tao Y; Huang Z; Zhang D; Zhao B; Chen C; Huang C; Gao X; Shen Q; Shen Y; Xu H;
Pediatr Nephrol; 2020 Nov; 35(11):2163-2171. PubMed ID: 32529322
[TBL] [Abstract][Full Text] [Related]
40. General characteristics and reasons for the discontinuation of drug clinical trials in mainland China.
Huo BN; Ai ML; Jia YT; Liu Y; Wang Y; Yin NG; Song L
BMC Med Res Methodol; 2021 Nov; 21(1):246. PubMed ID: 34773983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
